Literature DB >> 11219484

The role of the clinical pharmacologist in the management of adverse drug reactions.

N Moore1.   

Abstract

The classical definition of clinical pharmacology is the study or the knowledge of the effects of drugs in humans. The activities of a clinical pharmacologist can vary from country to country, usually ranging from involvement in clinical trials, especially fundamental pharmacodynamic studies, to studies of pharmacokinetics and drug metabolism, to pharmacogenetics. Most clinical pharmacologists outside industry are in hospitals or university hospitals and research centres. In addition to research, this implies teaching of clinical pharmacology, and interacting with other medical staff: in the field of research, giving advice on clinical trials methodology and often managing a therapeutic drug monitoring centre. Some clinical pharmacologists have clinical departments with beds or consulting offices. Can there be another role for the clinical pharmacologist that would increase his or her usefulness for the medical community? Adverse drug reactions (ADRs) are remarkably complex events, related to drug effects, patient characteristics (background diseases, genetics), and drug/disease interactions. Evaluation of ADRs requires understanding of drug mechanisms and interactions, and of disease diagnostics, especially in the discussion of alternative diagnoses. This implies expertise as a pharmacologist and a clinician. In addition, because not all adverse reactions or interactions are in the Summary of Product Characteristics, and because problems arise long before they report in the literature, it is necessary for the clinical pharmacologist to have knowledge of ongoing regulatory processes, in addition to having access to the published literature. Helping clinicians cope with individual patient problems will also improve the clinical pharmacologist's integration into the healthcare process.

Entities:  

Mesh:

Year:  2001        PMID: 11219484     DOI: 10.2165/00002018-200124010-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  23 in total

1.  Regional drug information service.

Authors:  U I Schwarz; S Stoelben; U Ebert; M Siepmann; J Krappweis; W Kirch
Journal:  Int J Clin Pharmacol Ther       Date:  1999-06       Impact factor: 1.366

2.  Excess costs related to non-steroidal anti-inflammatory drug utilization in general practice.

Authors:  N Moore; X Verschuren; C Montout; J Callens; S X Kong; B Bégaud
Journal:  Therapie       Date:  2000 Jan-Feb       Impact factor: 2.070

3.  Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs.

Authors:  J G Dartnell; R P Anderson; V Chohan; K J Galbraith; M E Lyon; P J Nestor; R F Moulds
Journal:  Med J Aust       Date:  1996-06-03       Impact factor: 7.738

4.  Spontaneous reporting of adverse drug reactions. II: Uses.

Authors:  M D Rawlins
Journal:  Br J Clin Pharmacol       Date:  1988-07       Impact factor: 4.335

5.  Adverse drug reaction monitoring: doing it the French way.

Authors:  N Moore; M Biour; G Paux; E Loupi; B Begaud; F Boismare; R J Royer
Journal:  Lancet       Date:  1985-11-09       Impact factor: 79.321

Review 6.  [The Spanish drug surveillance system].

Authors:  J R Laporte; D Capellà
Journal:  Med Clin (Barc)       Date:  1994-09-24       Impact factor: 1.725

7.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

8.  Frequency and cost of serious adverse drug reactions in a department of general medicine.

Authors:  N Moore; D Lecointre; C Noblet; M Mabille
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

9.  Prescribing for older patients: how to avoid toxic drug reactions.

Authors:  I L Salom; K Davis
Journal:  Geriatrics       Date:  1995-10

10.  [Drug information and prescription guidance: role of regional centers of pharmacovigilance].

Authors:  J P Blayac; F Haramburu; S Lerebours; T Vial
Journal:  Presse Med       Date:  2000-01-22       Impact factor: 1.228

View more
  10 in total

Review 1.  Methods and systems to detect adverse drug reactions in hospitals.

Authors:  P A Thürmann
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Assessing drug safety.

Authors:  Nicholas Moore
Journal:  BMJ       Date:  2005-03-05

3.  Influence of pharmacists' attitudes on adverse drug reaction reporting : a case-control study in Portugal.

Authors:  Maria T Herdeiro; Adolfo Figueiras; Jorge Polónia; J J Gestal-Otero
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Merck fellowships contribute to the continued growth of clinical pharmacology in Sweden.

Authors:  Folke Sjöqvist; Lars-Olof Eriksson; Karl-Erik Andersson
Journal:  Eur J Clin Pharmacol       Date:  2007-01-18       Impact factor: 2.953

5.  Characteristics and apprehensions of clinical pharmacologists in Swedish healthcare--a questionnaire study.

Authors:  Susanna M Wallerstedt; Staffan Rosenborg
Journal:  Eur J Clin Pharmacol       Date:  2013-05-03       Impact factor: 2.953

6.  Spontaneous adverse drug reaction reporting in rural districts of Mozambique.

Authors:  Esperança Sevene; Alda Mariano; Ushma Mehta; Maria Machai; Alexander Dodoo; David Vilardell; Sam Patel; Karen Barnes; Xavier Carné
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

7.  Pharmacovigilance: a worldwide master key for drug safety monitoring.

Authors:  G Jeetu; G Anusha
Journal:  J Young Pharm       Date:  2010-07

Review 8.  Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance.

Authors:  Ram Kumar Sahu; Rajni Yadav; Pushpa Prasad; Amit Roy; Shashikant Chandrakar
Journal:  Springerplus       Date:  2014-11-26

9.  An opportunity for clinical pharmacology trained physicians to improve patient drug safety: A retrospective analysis of adverse drug reactions in teenagers.

Authors:  Andy R Eugene; Beata Eugene
Journal:  F1000Res       Date:  2018-05-30

10.  Evaluation of potential drug-drug interactions in a pediatric population.

Authors:  Berna Terzioğlu Bebitoğlu; Elif Oğuz; Çağatay Nuhoğlu; Ayşe Ela Kurtdan Dalkılıç; Pelin Çirtlik; Fatime Temel; Ajla Hodzic
Journal:  Turk Pediatri Ars       Date:  2020-03-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.